Amygdala Neurofeedback for Depression - Large Scale Clinical Trial

Description

The goal of this study is to evaluate whether rtfMRI-nf training to increase the amygdala response to positive memories may serve as a stand-alone intervention for major depressive disorder

Conditions

Major Depressive Disorder

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this study is to evaluate whether rtfMRI-nf training to increase the amygdala response to positive memories may serve as a stand-alone intervention for major depressive disorder

Confirmatory Efficacy Randomized Clinical Trial of Amygdala Neurofeedback for Major Depressive Disorder

Amygdala Neurofeedback for Depression - Large Scale Clinical Trial

Condition
Major Depressive Disorder
Intervention / Treatment

-

Contacts and Locations

Pittsburgh

University of Pittsburgh, Pittsburgh, Pennsylvania, United States, 15261

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * ages 18 - 55
  • * primary diagnosis of MDD and are currently depressed
  • * able to give written informed consent prior to participation
  • * unmedicated OR are stable on an antidepressant regime (at least 4 weeks to ensure symptoms are stable). Effective medications will not be discontinued for the purposes of the study.
  • * clinically significant or unstable cardiovascular, pulmonary, endocrine, neurological, gastrointestinal illness or unstable medical disorder
  • * Current severe DSM-V alcohol or substance use disorder, with the exception of nicotine or caffeine. Clinician will access subjects' alcohol and substance use on a case-by-case to determine whether specific cases of mild or moderate alcohol or substance use would also interfere with the effects of the intervention.
  • * history of traumatic brain injury
  • * unable to complete MRI scan due to claustrophobia or general MRI exclusions (e.g., shrapnel inside body)
  • * currently pregnant or breast feeding
  • * unable to complete questionnaires written in English
  • * current (within 3 weeks of testing) use of any antipsychotics, anticonvulsants, stimulants, benzodiazepines, beta-blockers, or other medications (except antidepressants) likely to influence cerebral blood flow. Effective medications will not be discontinued for the purposes of the study.
  • * diagnosis of psychotic or organic mental disorder, bipolar I or II disorder.
  • * eye problems or difficulties in corrected vision.

Ages Eligible for Study

18 Years to 55 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Kymberly Young,

Kymberly Young, PhD, PRINCIPAL_INVESTIGATOR, University of Pittsburgh

Study Record Dates

2028-04-30